Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The New Oncology Model Created to Improve Cancer Care

For anyone working in the oncology field, a highly anticipated change set to take place will be one of the biggest transitions in recent years. Last year, it was announced that the Oncology Care Model (OCM) will be phased out and succeeded with the Enhanced Oncology Model (EOM). This new model will go into effect…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Carevive on MarketScale.

Share
The New Oncology Model Created to Improve Cancer Care

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

For anyone working in the oncology field, a highly anticipated change set to take place will be one of the biggest transitions in recent years. Last year, it was announced that the Oncology Care Model (OCM) will be phased out and succeeded with the Enhanced Oncology Model (EOM). This new model will go into effect in July 2023 and help improve care for cancer patients.

What are the people who work in the oncology field most looking forward to with the forthcoming new model implementation? And what are their expectations for cancer care?

In the latest episode of “Oncology and Technology,” host Tyler Kern sat down to interview with several members of the Carevive team, John Elliot, VP of Sales; Reesa Sherin, Clinical Strategist; and April Boyd, Clinical Product Manager, mostly about the state of the oncology, and what current trends will remain or seeing advancements next year.

Kern, Elliot, Sherin, and Boyd also talked about …

  1. Educational events held in preparation for the shift to EOM
  2. What clinicians will value in terms of the new models and how they expect to implement
  3. How the shift will change oncology and cancer patient care

“The big shift, I think, just in healthcare broadly and then specifically to oncology, has been continued evaluation and how health systems and cancer centers are evaluating a shift to value-based care from the traditional … service,” said Elliot.

John Elliot is the Vice President of Sales at Carevive. He has been with the company for almost four years and held a previous senior position at Cerner Corporation. Elliot is a graduate of Southern Methodist University and Washington University in St. Louis – Olin Business School.

Reesa Sherin is Carevive’s Clinical Strategist and is a MSN and RN. She has been with the company for six years and is a graduate of Temple University and Thomas Jefferson University.

April Boyd is the Clinical Product Manager at Carevive and has been in that role for three years now. Prior to that she worked at the MD Anderson Cancer Center.

Carevive

Part of this channel

Carevive

Remote oncology monitoring that connects clinicians and cancer patients between visits.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512